SCHEMBL6836709

SCHEMBL6836709

CCOC(=O)c1cc2c(C=O)ccc(OC)c2o1

nearest known ligand 0.45

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
ERN1 O75460 3/20 0.45
AKR1B1 P15121 1/20 0.41
HSD17B2 P37059 1/20 0.40
GPR35 Q9HC97 1/20 0.40
MAOB P27338 1/20 0.40
HTT P42858 1/20 0.39
LMNA P02545 2/20 0.39
RECQL P46063 1/20 0.39
ALOX5 P09917 1/20 0.39
ALDH1A1 P00352 2/20 0.39
CYP1A2 P05177 1/20 0.39
CYP2C19 P33261 1/20 0.39
SMN1; SMN2 Q16637 1/20 0.39
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
TSHR P16473 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4089689 0.90 ERN1 (0.45) ERN1AKR1B1HSD17B2GPR35MAOB
SCHEMBL7055204 0.87 LMNA (0.48) ERN1LMNARECQLALDH1A1PDE4A
SCHEMBL27297405 0.85 ERN1 (0.47) ERN1AKR1B1HSD17B2MAOBLMNA
SCHEMBL27297403 0.84 KDM4E (0.47) ERN1MAOBLMNAALDH1A1
SCHEMBL6837533 0.83 PDE4A (0.49) ERN1GPR35LMNARECQLALDH1A1
SCHEMBL16345218 0.82 LMNA (0.43) AKR1B1HSD17B2GPR35MAOBHTT
SCHEMBL6839386 0.81 PDE4A (0.48) AKR1B1HSD17B2GPR35MAOBPDE4A
SCHEMBL27252712 0.80 ERN1 (0.47) ERN1AKR1B1HSD17B2MAOBLMNA
SCHEMBL6837725 0.78 RAB9A (0.60) ERN1HTTLMNARECQLALDH1A1
SCHEMBL27185388 0.77 LMNA (0.43) AKR1B1HSD17B2GPR35MAOBHTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6716987-B1 PHOSPHODIESTERASE IV INHIBITORS KYOWA HAKKO KOGYO CO., LTD. (JP) 2004-04-06 US disclosed
EP-1029860-B1 BENZOFURAN DERIVATIVES KYOWA HAKKO KOGYO KK (JP) 2003-04-16 EP disclosed
US-6514996-B2 Derivatives of benzofuran or benzodioxole KYOWA HAKKO KOGYO CO., LTD. (JP) 2003-02-04 US disclosed
US-20020128290-A1 DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-09-12 US disclosed
US-6395738-B1 ANTIINFLAMMATORY, ANTIALLERGENS KYOWA HAKKO KOGYO CO., LTD. (JP) 2002-05-28 US disclosed
EP-1029860-A1 BENZOFURAN DERIVATIVES KYOWA HAKKO KOGYO CO., LTD. (JP) 2000-08-23 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20020128290-A1 DERIVATIVES OF BENZOFURAN OR BENZODIOXOLE CBR1, CBR3, CYC1 ERN1 880/4885AKR1B1 246/4885HSD17B2 85/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.